Literature DB >> 14647440

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.

Tetsuji Nakagawachi1, Hidenobu Soejima, Takeshi Urano, Wei Zhao, Ken Higashimoto, Yuji Satoh, Shiroh Matsukura, Shinichi Kudo, Yoshihiko Kitajima, Haruhito Harada, Koichi Furukawa, Hideki Matsuzaki, Mitsuru Emi, Yusaku Nakabeppu, Kohji Miyazaki, Mutsuo Sekiguchi, Tsunehiro Mukai.   

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) repairs the cytotoxic and mutagenic O6-alkylguanine produced by alkylating agents such as chemotherapeutic agents and mutagens. Recent studies have shown that in a subset of tumors, MGMT expression is inversely linked to hypermethylation of the CpG island in the promoter region; however, how the epigenetic silencing mechanism works, as it relates to hypermethylation, was still unclear. To understand the mechanism, we examined the detailed methylation status of the whole island with bisulfite-sequencing in 19 MGMT non-expressed cancer cell lines. We found two highly methylated regions in the island. One was upstream of exon 1, including minimal promoter, and the other was downstream, including enhancer. Reporter gene assay showed that methylation of both the upstream and downstream regions suppressed luciferase activity drastically. Chromatin immunoprecipitation assay revealed that histone H3 lysine 9 was hypermethylated throughout the island in the MGMT negative line, whereas acetylation on H3 and H4 and methylation on H3 lysine 4 were at significantly high levels outside the minimal promoter in the MGMT-expressed line. Furthermore, MeCP2 preferentially bound to the CpG-methylated island in the MGMT negative line. Given these results, we propose a model for gene silencing of MGMT that is dependent on the epigenetic state in cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647440     DOI: 10.1038/sj.onc.1207183

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

1.  Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer.

Authors:  Kazumori Kawakami; Soichiro Yamamura; Hiroshi Hirata; Koji Ueno; Sharanjot Saini; Shahana Majid; Yuichiro Tanaka; Ken Kawamoto; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 2.  MGMT promoter methylation in malignant gliomas.

Authors:  Markus J Riemenschneider; Monika E Hegi; Guido Reifenberger
Journal:  Target Oncol       Date:  2010-08-20       Impact factor: 4.493

3.  CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.

Authors:  S M Pulukuri; J S Rao
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

4.  Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.

Authors:  H Pinson; G Hallaert; J Van der Meulen; F Dedeurwaerdere; D Vanhauwaert; C Van den Broecke; J Van Dorpe; D Van Roost; J P Kalala; T Boterberg
Journal:  J Neurooncol       Date:  2019-11-07       Impact factor: 4.130

5.  MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.

Authors:  Lichy Han; Maulik R Kamdar
Journal:  Pac Symp Biocomput       Date:  2018

6.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

7.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

8.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

9.  Stc1: a critical link between RNAi and chromatin modification required for heterochromatin integrity.

Authors:  Elizabeth H Bayne; Sharon A White; Alexander Kagansky; Dominika A Bijos; Luis Sanchez-Pulido; Kwang-Lae Hoe; Dong-Uk Kim; Han-Oh Park; Chris P Ponting; Juri Rappsilber; Robin C Allshire
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

10.  MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines.

Authors:  Mario Dandrea; Massimo Donadelli; Chiara Costanzo; Aldo Scarpa; Marta Palmieri
Journal:  Nucleic Acids Res       Date:  2009-09-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.